“What have you ever completed for me currently, Lou?”
That’s a typical chorus I hear from readers of my FREE newsletters. I get it. Readers are all the time in search of extra nice suggestions without cost.
And candidly, I can’t blame them. In a world stuffed with noise and pretenders, being skeptical about shopping for premium analysis is sensible.
So earlier than you plunk down your hard-earned cash for any paid suggestions, you need your “funding guru” to show his or her price with some free profitable picks.
Why do I convey this up at present? Easy. As a result of I’ve acquired some extra free picks to offer you!
But additionally as a result of I’ve two questions for you — specifically:
Will you act on this data I’m supplying you with?
And extra importantly, will it’s sufficient?
You’ve Obtained to be in It to Win It
Final week, I hosted an hour-long Portfolio Overview & Future Know-how Outlook webinar for subscribers of my premium analysis advisory, Micro-Cap Benefit.
Throughout the subscriber-only occasion, I shared the High three sectors to focus on for max positive aspects within the subsequent few months.
The primary sector shouldn’t come as a shock to you — it’s biotech.
As you already know, after first predicting it will be a top-performing sector all of the approach again in April, I’ve been writing about biotech on this column for weeks now.
(In case you pulled a Rip Van Winkle and missed my analysis about why biotech is a red-hot funding alternative — proper now, and for the foreseeable future — you may catch up shortly right here and right here.)
And right here’s yet another piece of knowledge so as to add to the overwhelmingly bullish set-up into year-end and 2021:
As Bruce Sales space of Life Sci VC writes, “We’ve witnessed a tsunami of funding flows into the [biotech] sector. Whereas different sectors have additionally skilled the exuberance of market appreciation, biotech’s buoyancy has exceeded most others.”
Certainly! And it’s persevering with, significantly within the public markets.
Living proof: Biotech firms have accounted for 20% of all the cash raised this yr from IPOs and follow-on choices, and 40% of the general offers. In different phrases, the vast majority of funding rounds getting completed proper now are for biotech firms.

Put merely, the good cash is piling into biotech at a quickening tempo. And as I’ve shared earlier than, being a worthwhile development dealer means following large cash flows, irrespective of the place they’re going.
A clearer “purchase” sign out there merely doesn’t exist proper now.
So — will you act on it?
Three (Free) Methods to Play the Biotech Increase
I ask as a result of, should you’ve been paying shut consideration to Development Dealer Each day, you already know that I’ve already shared two methods in earlier columns to soundly play this development:
The Principal Healthcare Innovators Index ETF (BTEC) and the SPDR S&P Biotech ETF (XBI).
Each are up a strong 6% in simply the 2 weeks since I beneficial them, with loads extra room to run.
After all, I don’t simply give away free data and picks on this column…
I additionally do it throughout my stay displays!
For instance, should you tuned into my occasion final week (the one the place I informed you upfront that I’d be sharing “the most secure biotech inventory to personal at present”), you’d be sitting on a 10% acquire and counting.
And once more, that’s in only one week’s time.
I’ve shared loads of alternatives outdoors of biotech, too.
For instance, should you’d tuned into my October 21st “Again to Your Monetary Future” occasion, you’d have been given free analysis that included the title, ticker image, and particular shopping for directions for a tech firm on the epicenter of the $188 billion anti-counterfeiting market.
And should you acted on that free data, you’d now be sitting on income of 61% and counting!
The record of my free suggestions for you goes on and on. For instance:
- 10 days in the past, I informed you to quick Zoom Video Communications, Inc. (ZM) forward of its quarterly report. Pull up the ticker at present. It’s down about 17.5%. In a single day.
- A couple of weeks earlier than that, I informed you to scoop up shares of LAM Analysis Corp. (LRCX), based mostly on the uptick in semiconductor tools gross sales. And that inventory is up virtually 50% already.
Did you act on any of those trades? I actually hope so!
And if that’s the case, at what level will I earn sufficient of your confidence to earn your enterprise?
Solely you already know that reply.
However I can inform you this: my premium readers are having fun with considerably increased income than my free readers.
For instance, on common, my picks for my premium biotech service have soared greater than 300% this yr.
And lots of of my picks for my premium micro-cap service are already up by triple-digits and counting.
Should you’re certainly one of my premium readers, thanks to your vote of confidence.
However should you’re nonetheless on the fence, what are you ready for?
Be a part of Me Tonight
Later tonight, I’m internet hosting my final LIVE occasion of the yr…
And guess what?
Throughout this particular on-line Zoom, I’ll be sharing a biotech funding alternative, without cost.
To get all the data that you must make this commerce, you merely have to register for my occasion, and attend stay.
To register earlier than it’s too late, click on right here now »
And earlier than the week is out, I plan to disclose two extra traits for max positive aspects heading into year-end.
Will that be sufficient?
For the sake of my enterprise — and for the sake of your income — I actually and sincerely hope so!
Forward of the tape,

Lou Basenese
Feedback